secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2023-09-28T23:59:59+00:00
Accession:  0001070081-23-000053
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics cuts 25% workforce, targets 20% OPEX reduction
---------------------------------------------------------------

- Workforce reduction of ~25% primarily in US early-stage research and gene therapy manufacturing.
- Estimated severance and benefit costs of ~$21M, substantially all cash expenditures.
- Annualized operating expenses expected to drop ~20% vs 2023 OPEX guidance.
- Plans to submit re-examination request for CHMP negative opinion on Translarna.
- Reduction substantially complete by January 15, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/0001070081-23-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008123000053/tmb-20230928x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-23-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer